Država: Novi Zeland
Jezik: engleski
Izvor: Medsafe (Medicines Safety Authority)
Ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g
AFT Pharmaceuticals Ltd
2 g
Powder for injection
Active: Ceftazidime pentahydrate 2.33 g equivalent to ceftazidime 2g Excipient: Sodium carbonate
Prescription
Indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. May be used alone as first choice medicine before the results of sensitivity tests are available. May be used in combination with an aminoglycoside or most other beta-lactam antibiotics. May be used with an antibiotic against anaerobes when the presence of Bacteroides fragilis is suspected. Susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. Indications include: - Severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - Respiratory tract infections including lung infections in cystic fibrosis. - Ear, nose and throat infections. - Urinary tract infections. - Skin and soft tissue infections. - Gastrointestinal, biliary, and abdominal infections. - Bone and joint infections. - Infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD)
Package - Contents - Shelf Life: Vial, glass, single dose, Type III Soda-lime, 1x2g vial - 1 dose units - 24 months from date of manufacture stored at or below 25°C protect from light - Vial, glass, single dose, Type III Soda-lime, 5x2g vial - 5 dose units - 24 months from date of manufacture stored at or below 25°C protect from light - Vial, glass, single dose, Type III Soda-lime, 10x2g vial - 10 dose units - 24 months from date of manufacture stored at or below 25°C protect from light
2018-01-08
NEW ZEALAND DATA SHEET 1. PRODUCT NAME CEFTAZIDIME-AFT ceftazidime (as pentahydrate) 1 g or 2 g powder for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTAZIDIME-AFT powder for injection contains either 1 g or 2 g of ceftazidime (as pentahydrate). For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for injection. A white or almost white crystalline powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CEFTAZIDIME-AFT is indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. May be used alone as first choice medicine before the results of sensitivity tests are available. May be used in combination with an aminoglycoside or most other beta-lactam antibiotics. May be used with an antibiotic against anaerobes when the presence of _Bacteroides fragilis _ is suspected. Susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 Pharmacodynamic properties). Indications include: • Severe infections e.g. • - septicaemia, bacteraemia, peritonitis, meningitis. • - infections in immunosuppressed patients. • - infections in patients in intensive care, e.g. infected burns. • Respiratory tract infections including lung infections in cystic fibrosis. • Ear, nose and throat infections. • Urinary tract infections. • Skin and soft tissue infections. • Gastrointestinal, biliary and abdominal infections. • Bone and joint infections. • Infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD). 4.2 DOSE AND METHOD OF ADMINISTRATION Dose Dosage depends upon the severity, sensitivity, site and type of infection and upon the age and renal function of the patient. ADULTS: 1-6 g/day in 2 or 3 divided doses by intravenous (i.v.) or intramuscular (i.m.) injection. Urinary tract and less severe infections: • 500 mg or 1 g every 12 ho Pročitajte cijeli dokument